These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19883313)

  • 1. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma.
    Brown RD; Spencer A; Ho PJ; Kennedy N; Kabani K; Yang S; Sze DM; Aklilu E; Gibson J; Joshua DE
    Leuk Lymphoma; 2009 Nov; 50(11):1860-4. PubMed ID: 19883313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.
    Herth I; Witzens-Harig M; Beckhove P; Hose D; Meissner T; Neuber B; Engelhardt M; Haas J; Neben K; Ho AD; Klein B; Goldschmidt H; Hundemer M
    Exp Hematol; 2013 Mar; 41(3):231-40. PubMed ID: 23142220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
    van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
    Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
    Goldschmidt H; Lokhorst HM; Mai EK; van der Holt B; Blau IW; Zweegman S; Weisel KC; Vellenga E; Pfreundschuh M; Kersten MJ; Scheid C; Croockewit S; Raymakers R; Hose D; Potamianou A; Jauch A; Hillengass J; Stevens-Kroef M; Raab MS; Broijl A; Lindemann HW; Bos GMJ; Brossart P; van Marwijk Kooy M; Ypma P; Duehrsen U; Schaafsma RM; Bertsch U; Hielscher T; Jarari L; Salwender HJ; Sonneveld P
    Leukemia; 2018 Feb; 32(2):383-390. PubMed ID: 28761118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.
    Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA;
    Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma.
    Sahebi F; Spielberger R; Kogut NM; Fung H; Falk PM; Parker P; Krishnan A; Rodriguez R; Nakamura R; Nademanee A; Popplewell L; Frankel P; Ruel C; Tin R; Ilieva P; Forman SJ; Somlo G
    Bone Marrow Transplant; 2006 May; 37(9):825-9. PubMed ID: 16565743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
    Yakoub-Agha I; Attal M; Dumontet C; Delannoy V; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux V; Bay JO; Monconduit M; Harousseau JL; Duguet C; Duhamel A; Facon T
    Hematol J; 2002; 3(4):185-92. PubMed ID: 12189564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire.
    Pérez-Andres M; Almeida J; Martin-Ayuso M; Moro MJ; Martin-Nuñez G; Galende J; Hernandez J; Mateo G; San Miguel JF; Orfao A; ;
    Cancer; 2006 Mar; 106(6):1296-305. PubMed ID: 16475149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.
    Mian I; Milton DR; Shah N; Nieto Y; Popat UR; Kebriaei P; Parmar S; Oran B; Shah JJ; Manasanch EE; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
    Cancer; 2016 Dec; 122(24):3831-3837. PubMed ID: 27680710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Maintenance therapies of thalidomine and interferon-α in multiple myeloma].
    Li J; Cai JH; Huang BH; Liu JR; Zheng D
    Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(48):3417-20. PubMed ID: 22333255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
    Ho PJ; Brown RD; Spencer A; Jeffels M; Daniher D; Gibson J; Joshua DE
    Leuk Lymphoma; 2012 Sep; 53(9):1728-34. PubMed ID: 22329352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden.
    Halapi E; Werner A; Wahlström J; Osterborg A; Jeddi-Tehrani M; Yi Q; Janson CH; Wigzell H; Grunewald J; Mellstedt H
    Eur J Immunol; 1997 Sep; 27(9):2245-52. PubMed ID: 9341766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommend maintenance therapy with lenalidomide in multiple myeloma.
    Manasanch EE
    Semin Oncol; 2016 Dec; 43(6):712-713. PubMed ID: 28061994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells.
    Raitakari M; Brown RD; Sze D; Yuen E; Barrow L; Nelson M; Pope B; Esdale W; Gibson J; Joshua DE
    Br J Haematol; 2000 Jul; 110(1):203-9. PubMed ID: 10930999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
    Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
    Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.